RSLS | tickerfilter.com

Fundamental analysis

12%

Profitability 8%

Dept financing 11%

Liquidity 36%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

11.50%

1 Month

-17.39%

3 Months

-16.23%

6 Months

2,275.00%

1 Year

1,673.05%

2 Year

-21.36%

Key data

Stock price

$4.46

P/E Ratio

-0.52

DAY RANGE

$0.15 - $4.46

EPS

-$0.53

52 WEEK RANGE

$0.13 - $12.13

52 WEEK CHANGE

$1,802.28

MARKET CAP

4.731 M

YIELD

N/A

SHARES OUTSTANDING

29.387 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/06/2024

BETA

1.13

PUBLIC FLOAT

AVERAGE 10 VOLUME

$22,095

AVERAGE 30 VOLUME

$28,476

Company detail

CEO: Paul F. Hickey
Region: US
Website: reshapelifesciences.com
Employees: 50
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. Its product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes.

RSLS - ReShape Lifesciences Inc.